Preadmission use of nonaspirin nonsteroidal anti-inflammatory drugs and 30-day stroke mortality

Neurology

Volumn 83, Issue 22, 2014, Pages 2013-2022

  Schmidt, Morten ^a,b   Hováth Puhó, Erzsébet ^a   Christiansen, Christian Fynbo ^a   Petersen, Karin L ^b   Bøtker, Hans Erik ^a   Sørensen, Henrik Toft ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMORBIDITY; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; STROKE PATIENT; SUBARACHNOID HEMORRHAGE; VERY ELDERLY; COHORT ANALYSIS; HEALTH SURVEY; HOSPITAL ADMISSION; PROCEDURES; STROKE; TIME; TRENDS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; PATIENT ADMISSION; POPULATION SURVEILLANCE; STROKE; TIME FACTORS;

EID: 84922482199     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001024     Document Type: Article

References (31)

1. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007; 82: 85-94.
2. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
3. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225-1236.
4. Park HK, Lee SH, Chu K, Roh JK. Effects of celecoxib on volumes of hematoma and edema in patients with primary intracerebral hemorrhage. J Neurol Sci 2009; 279: 43-46.
5. Ahmad M, Zhang Y, Liu H, Rose ME, Graham SH. Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. Brain Res 2009; 1279: 168-173.
6. Ayer R, Jadhav V, Sugawara T, Zhang JH. The neuroprotective effects of cyclooxygenase-2 inhibition in a mouse model of aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 2011; 111: 145-149.
7. McCullough L, Wu L, Haughey N, et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004; 24: 257-268.
8. Aid S, Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 2011; 93: 46-51.
9. Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Srensen HT. Existing data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 2012; 4: 303-313.
10. Schmidt M, Pedersen L, Srensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29: 541-549.
11. Schmidt M, Jacobsen JB, Johnsen SP, Btker HE, Srensen HT. Eighteen-year trends in stroke mortality and the prognostic influence of comorbidity. Neurology 2014; 82: 340-350.
12. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39(7 suppl): 30-33.
13. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007; 28: 150-154.
14. Schmidt M, Christiansen CF, Horvath-Puho E, Glynn RJ, Rothman KJ, Srensen HT. Non-steroidal antiinflammatory drug use and risk of venous thromboembolism. J Thromb Haemost 2011; 9: 1326-1333.
15. Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Srensen HT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 2011; 343: d3450.
16. Schmidt M, Hallas J, Friis S. Potential of prescription registries to capture individual-level use of aspirin and other non-steroidal anti-inflammatory drugs in Denmark: trends in utilization 1999-2012. Clin Epidemiol 2014; 6: 155-168.
17. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
18. Andersen KK, Andersen ZJ, Olsen TS. Predictors of early and late case-fatality in a nationwide Danish study of 26, 818 patients with first-ever ischemic stroke. Stroke 2011; 42: 2806-2812.
19. Andersen JS, Olivarius NDF, Krasnik A. The Danish National Health Service Register. Scand J Public Health 2011; 39(7 suppl): 34-37.
20. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Til S. Variable selection for propensity score models. Am J Epidemiol 2006; 163: 1149-1156.
21. Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg 2007; 134: 1128-1135.
22. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165: 978-984.
23. Wang Q, Tang G, Yenari M. The inflammatory response in stroke. J Neuroimmunol 2007; 184: 53-68.
24. Maddahi A, Kruse LS, Chen QW, Edvinsson L. The role of tumor necrosis factor-a and TNF-a receptors in cerebral arteries following cerebral ischemia in rat. J Neuroinflammation 2011; 8: 107.
25. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005; 5: 629-640.
26. Dori S, Otsuka T, Mito T, et al. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 2003; 54: 155-162.
27. Graham SH, Hickey RW. Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death. Arch Neurol 2003; 60: 628-630.
28. Kim EJ, Raval AP, Hirsch N, Perez-Pinzon MA. Ischemic preconditioning mediates cyclooxygenase-2 expression via nuclear factor-kappa B activation in mixed cortical neuronal cultures. Transl Stroke Res 2010; 1: 40-47.
29. Kim E, Raval AP, Defazio RA, Perez-Pinzon MA. Ischemic preconditioning via epsilon protein kinase C activation requires cyclooxygenase-2 activation in vitro. Neuroscience 2007; 145: 931-941.
30. Horiguchi T, Snipes JA, Kis B, Shimizu K, Busija DW. Cyclooxygenase-2 mediates the development of cortical spreading depression-induced tolerance to transient focal cerebral ischemia in rats. Neuroscience 2006; 140: 723-730.
31. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009; 7: 97.